Products

Data

Feature

Request Demo

Last update 08 May 2025

Viral antigens

Last update 08 May 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with Viral antigens

TVAX-008

Target

HBcrAg x L-HBsAg

Mechanism

HBcrAg inhibitors [+2]

Active Org.

Grand Theravac Life Science Nanjing Co. Ltd.

Originator Org.

Grand Theravac Life Science Nanjing Co. Ltd.

Active Indication

Hepatitis B, Chronic

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

mRNA-B-LNP(Chinese PLA Academy of Military Medical Sciences)

Target

MPXV A29L x MPXV A35R x MPXV B6R x MPXV M1R

Mechanism

MPXV A29L inhibitors [+3]

Active Org.

Chinese PLA Academy of Military Medical Sciences

Originator Org.

Chinese PLA Academy of Military Medical Sciences

Active Indication

Virus Diseases

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

EV-42

Target

Viral antigens

Mechanism

Viral antigens modulators

Active Org.-

Originator Org.

The Israel Institute for Biological Research

Active Indication

Orthopoxvirus infection

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Viral antigens

CTR20231429

/ RecruitingPhase 2

在经治慢性乙型肝炎患者中评估 TVAX-008 注射液治疗有效性和安全性的多中心、随机、双盲、安慰剂平行对照II 期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of TVAX-008 injection in patients with previously treated chronic hepatitis B

主要目的：评价 TVAX-008 注射液治疗核苷（酸）类似物（NAs）经治的慢性乙型肝炎患者的有效性。次要目的：评价 TVAX-008 注射液治疗核苷（酸）类似物（NAs）经治的慢性乙型肝炎患者的安全性。

[Translation]

Primary objective: To evaluate the efficacy of TVAX-008 injection in the treatment of chronic hepatitis B patients who have been treated with nucleoside (acid) analogs (NAs). Secondary objective: To evaluate the safety of TVAX-008 injection in the treatment of chronic hepatitis B patients who have been treated with nucleoside (acid) analogs (NAs).

Start Date30 May 2023

Sponsor / Collaborator

Grand Theravac Life Science Nanjing Co. Ltd.

CTR20202547

/ CompletedPhase 1

TVAX-008注射液在慢性乙肝患者中的安全性,耐受性和药代动力学特征观察的I期临床试验

[Translation] A Phase I clinical trial to observe the safety, tolerability and pharmacokinetic characteristics of TVAX-008 injection in patients with chronic hepatitis B

主要研究目的:评估TVAX-008注射液的安全性,耐受性和药代动力学(PK)特征. 次要研究目的:评估TVAX-008注射液佐剂的安全性,耐受性和药代动力学(PK)特征. 探索性研究目的:1,初步观察TVAX-008注射液在慢性乙肝患者中的有效性. 2,探索与TVAX-008注射液疗效相关的免疫学标志物. 3,探索II期临床试验推荐用药剂量.

[Translation]

Main research objectives: To evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of TVAX-008 injection. Secondary research objectives: To evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of TVAX-008 injection adjuvant. Exploratory research objectives: 1. Preliminary observation of the effectiveness of TVAX-008 injection in patients with chronic hepatitis B. 2. To explore immunological markers related to the efficacy of TVAX-008 injection. 3. To explore the recommended dosage for Phase II clinical trials.

Start Date26 Jan 2021

Sponsor / Collaborator

Grand Theravac Life Science Nanjing Co. Ltd.

NCT03829384

/ CompletedPhase 1

A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults

This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects. Cohorts of mRNA-1944 are planned to be investigated in a sequential dose escalation manner.

Start Date22 Jan 2019

Sponsor / Collaborator

ModernaTX, Inc.

100 Clinical Results associated with Viral antigens

100 Translational Medicine associated with Viral antigens

0 Patents (Medical) associated with Viral antigens

541

Literatures (Medical) associated with Viral antigens

31 Dec 2025·Emerging Microbes & Infections

An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge

Article

Author: Li, Entao ; Zhou, Jinge ; Yang, Qiyuan ; Gong, Qizan ; Zhang, Jiachen ; Chiu, Sandra ; Wang, Yucai ; Guo, Xiaoping ; Chuai, Xia ; Xie, Wenyu

Assessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including the induction of MPXV A35/B6/A29/M1-specific IgG antibodies, VACV neutralizing antibodies and activated cytotoxic CD8⁺T cells, which provides 100% protection against lethal VACV challenge even at 280 days after the first vaccination. Our results provide critical insights for orthopoxvirus vaccine development.

01 Dec 2025·Endocrine Pathology

Evaluating CK20 and MCPyV Antibody Clones in Diagnosing Merkel Cell Carcinoma

Article

Author: Ozluk, Yasemin ; Kozanoglu, Erol ; Yeni Erdem, Begum ; Buyukbabani, Nesimi ; Baykal, Can ; Ozturk Sari, Sule ; Ahmed, Melin A ; Saip, Pinar

AbstractMerkel cell carcinoma (MCC) is diagnosed through histopathological and immunohistochemical examination of biopsies from skin or other organs. Its distinguishing features include perinuclear dot-like staining with Cytokeratin 20 (CK20) and detection of Merkel cell polyomavirus (MCPyV) using various methods. However, CK20 and MCPyV negative MCC cases have been reported at varying rates. In this single center cross-sectional study, we aimed to determine which clones are more effective in diagnosing MCC by comparing the performance of CK20 antibody clones Ks20.8 and SP33, as well as MCPyV antibody clones Ab3 and CM2B4. Fifty-four patients diagnosed with MCC were included. Among these, 42 cases were primary cutaneous, and 12 cases were nodal MCC. Fifty-two (96.3%) cases were positive with both CK20 clones, while two cases were negative. Clone SP33 stained areas of necrosis, whereas Ks20.8 showed no aberrant staining. MCPyV was detected in 44 cases (81.5%) using clone Ab3 and 39 cases (72.2%) using clone CM2B4. Staining with MCPyV clone Ab3 was diffuse and strong in most cases, while approximately 30% of CM2B4-positive cases exhibited low percentages and/or weak staining, complicating the evaluation. The two CK20-negative cases were also negative with both MCPyV clones. Our data demonstrated that CK20 clone Ks20.8 may be preferred for MCC diagnosis due to its consistent performance and lack of aberrant staining. Similarly, MCPyV clone Ab3 appears superior to CM2B4 for identifying MCPyV-positive cases.

01 Jun 2025·Biosensors and Bioelectronics

Development of a single-tube RPA/CRISPR-cas12a detection platform for monkeypox virus

Article

Author: Choi, Jeong-Woo ; Guo, Jinhong ; Li, Chenzhong ; Yang, Yang ; Liu, Shan ; Luo, Hongzhi ; Li, Xue

Monkeypox is a zoonotic disease caused by the monkeypox virus (MPXV), with outbreaks primarily occurring in West and Central Africa. The recent global MPXV outbreak underscores the urgent need for effective detection methods. Currently, qPCR is considered the gold standard for MPXV detection; however, it requires specialized personnel and costly equipment. This study introduces a CRISPR-Cas12a-based detection system targeting the MPXV A27L gene, achieving a detection limit as low as 10 aM. This system exhibits high specificity, with no cross-reactivity with other orthopoxviruses, and delivers results in under 40 min. To support point-of-care testing (POCT), we developed a lateral flow assay (LFA) strip for easy result visualization. The detection system was validated using six different clinical sample types, revealing that herpes fluid and saliva are the most suitable sources. The findings of this study align with qPCR results. Additionally, we lyophilized the RPA and CRISPR reagents to improve transport, storage, and field deployment. In conclusion, this study presents a reliable molecular diagnostic approach for early MPXV detection and point-of-care testing, contributing to epidemic prevention and control.

News (Medical) associated with Viral antigens

23 Apr 2025

·investor.arbutusbio.com

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET. Abstract Number: 1768 Title: IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therapy Presenter: Prof. Man-Fung Yuen Presentation Date: May 8, 2025 Key Findings: Within this small group of subjects who achieved functional cure or HBV DNA

Clinical ResultPhase 2siRNA

26 Mar 2025

·www.globenewswire.com

Aligos Therapeutics Presents Positive Data at APASL 2025

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. “We are pleased to present preliminary data out to 96 weeks in our Phase 1 study of ALG-000184, which continues to demonstrate first-/best-in-class reductions in important HBV markers,” stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. “Additionally, the HERALD data from the Phase 2a study of ALG-055009 in MASH subjects demonstrated robust reductions in liver fat, with a subgroup analysis in subjects on stable GLP-1 agonist therapy, showing a potential role for ALG-055009 in combination with other therapies.” Two oral presentations will highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both HBeAg-positive and HBeAg-negative subjects, demonstrating the potential for the molecule to become first-line therapy for chronic suppression and the backbone for regimens aimed at functional cure. Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated HBV DNA suppression (

Clinical ResultPhase 2Phase 1

19 Nov 2024

·www.globenewswire.com

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. The clinical poster presentation highlighted the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) virus infection in both HBeAg-positive and HBeAg-negative subjects, demonstrating the potential for the molecule to become first-line therapy for chronic suppression and the backbone for regimens aimed at functional cure. Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Clinical ResultPhase 2

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us: phs@patsnap.com

What we do

Drug
Clinical Progress
Patent
Literature
Report
News

Viral antigens

Basic Info

Related

Analysis